2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors

Background

Seizure-related 6 homolog (SEZ6) is overexpressed in many tumor types with high unmet need, including small cell lung cancer (SCLC), neuroendocrine carcinomas (NECs), and central nervous system (CNS) tumors. ABBV-706 is an antibody-drug conjugate (ADC) comprised of an anti-SEZ6 antibody conjugated to a topoisomerase 1 inhibitor payload.

Trial design

This is an open-label, phase 1, first-in-human, dose-escalation, and expansion study (NCT05599984). The study will evaluate the preliminary safety, tolerability, pharmacokinetics (PK), and antitumor activity of ABBV-706 as monotherapy and in combination with budigalimab (a PD-1 inhibitor), carboplatin, or cisplatin, and determine the recommended phase 2 dose (RP2D) of ABBV-706. The study has 4 parts: (1) ABBV-706 monotherapy dose escalation in relapsed or refractory (R/R) solid tumors, following the Bayesian optimal interval (BOIN) design; (2) monotherapy dose optimization, randomized between two or more dose levels, and expansion in R/R SCLC; (3) dose escalation and expansion of ABBV-706 in combination with budigalimab or platinum therapy in R/R SCLC and NECs; (4) monotherapy dose expansion in R/R high-grade CNS tumors or NECs. Safety endpoints include adverse events, clinical laboratory tests, vital signs, and dose-limiting toxicities. PK endpoints include C_max, t_max, t_1/2, and AUC. Primary efficacy endpoints include objective response rate and duration of response. Clinical benefit rate, progression-free survival, overall survival, and biomarkers will also be evaluated. ABBV-706 will be administered intravenously until disease progression, withdrawal of consent, or unacceptable toxicity. Trial Eligibility: adults ≥18 years old with R/R SCLC, NECs (including neuroendocrine prostate cancer), or high-grade CNS tumors and measurable disease per RECIST v1.1 or RANO, with an ECOG score ≤1. Tumor tissue submission for retrospective SEZ6 expression analysis is required. The study began in December 2022 and enrollment is ongoing.

Clinical trial identification

NCT05599984.

Editorial acknowledgement

Medical writing support was provided by Heather Hultzapple, Pharm D of Fishawack Ltd, funded by AbbVie, Inc.

Legal entity responsible for the study

AbbVie.

Funding

ABBV-706 is being developed by AbbVie. AbbVie funded this study and participated in the study design, as well as the writing, review, and approval of the publication. No honoraria or payments were made for authorship.

Disclosure

S. Chandana: Financial Interests, Personal and Institutional, Speaker’s Bureau: Natera. B. Garmezy: Financial Interests, Institutional, Research Grant: AbbVie, AstraZeneca, CRISPR Therapeutics, Exelixis, Genentech, Janssen, Loxo Oncology, Arcus Biosciences, Xencor, AVEO Oncology, Zenshire, Accutar Biotechnology, Kinnate Biopharma, Jubilant Therapeutics, Janux Therapeutics, Mink Therapeutics, Nuvation Bio, Profound Bio, Kineta; Financial Interests, Institutional, Other, Consulting: Amgen, Arvinas, Aveo, Bayer, Exelixis, Janssen, Merck, Sanofi-Aventis. A. Dowlati: Financial Interests, Personal, Advisory Board: Ipsen, BMS, AstraZeneca, Seattle Genetics, PUMA pharmaceuticals, Prelude Therapeutics. M.R. Sharma: Financial Interests, Personal and Institutional, Advisory Board: Pliant Therapeutics; Financial Interests, Personal, Stocks/Shares: AbbVie, Abbott Lab, Amgen, BMS, Gilead Sciences, Johnson & Johnson, Eli Lilly, Merck, Moderna, Pfizer, Regeneron, West Pharmaceutical; Financial Interests, Institutional, Research Grant: AbbVie, Agenus, Alpine Immune Sciences, ALX Oncology, Janssen, Ascentage Pharma Group, Boundless Bio, Seven and Eight Biopharmaceuticals, Bolt Biotherapeutics, Black Diamond Therapeutics, GSK, BMS, Celgene, Treadwell Therapeutics, Cullinan MICA, Compugen, Constellation Pharmaceuticals, CytomX Therapeutics, Debiopharm, Palleon Pharmaceuticals, eFFECTOR Therapeutics, Genmab, Arrys Therapeutics, Gilead Sciences, Helsinn Healthcare, Ikena Oncology, InhibRx, Jounce Therapeutics, Kinnate Biopharma, KSQ Therapeutics, Loxo Oncology, PureTech Health, Macrogenics, Merck, Alkermes, NGM Biopharmaceuticals, Onconova Therapeutics, Pfizer, Regeneron Pharmaceuticals, Repare Therapeutics, Servier, Seagen, Klus Pharma, SK Life Sciences, Shattuck Labs, Sapience Therapeutics, Syros Pharmaceuticals, Epizyme, Odonate Therapeutics, Theratechnologies, Tempest Therapeutics, Tizona Therapeutics, Exelixis, Mersana Therapeutics. W. Henner: Financial Interests, Personal, Full or part-time Employment: AbbVie; Financial Interests, Personal, Stocks/Shares: AbbVie. R. Robinson, E. Jeng: Financial Interests, Personal, Full or part-time Employment: AbbVie; Financial Interests, Personal, Stocks or ownership: AbbVie. K.P. Papadopoulos: Financial Interests, Institutional, Research Grant: 3D Medicines, AbbVie, ADC therapeutics, Amgen, Anheart Therapeutics, Bayer, Daiichi Sankyo, F-Star, Incyte, Jounce, Lilly Loxo, Merck, Mersana, Mirati, Pfizer, Regeneron, RevolutionMedicines, Syros Pharma, Tempest Therapeutics, Treadwell Therapeutics, CytomX, AstraZeneca, Kezar, Monte Rosa, Storm; Financial Interests, Personal, Advisory Board: Basilia, Bicycle, Turning Point Therapeutics. All other authors have declared no conflicts of interest.